Expert panel A range of stakeholders will be sought to establish the ED expert panel. The study team developed a list of stakeholder categories to identify the range of expertise required, such as physicians, nurses, dementia specialists or QI development experts (Table 1). In the first instance, one representative from each data collection site (field study) will be invited to participate in the panel. Purposeful sampling will follow, to populate each category with at least one representative. The total panel will include 12–18 participants. Potential participants will be contacted by email
with an explanation of the study and an invitation to join the expert Inhibitors,research,lifescience,medical panel. Panel members will be Inhibitors,research,lifescience,medical required to participate in two face-to-face expert panel meetings and a formal voting process, which will be conducted after the second panel meeting. Final Distribution of panel members is noted in Table 1. Table 1 Expert panel members Caspase inhibitor in vivo Design The scientific literature will be evaluated systematically to address 4 core concept areas: 1. Profile of elderly patients presenting to EDs including: patient characteristics; presenting complaints; discharge diagnoses;
discharge destinations; predictors of failed discharge from ED in elderly; predictors of morbidity & mortality Inhibitors,research,lifescience,medical within 28 days subsequent to ED discharge of elders 2. Descriptors of best practice in assessment and management of geriatric ED patients, in terms of process, environment Inhibitors,research,lifescience,medical and
structure including strength of relationship of each to desired outcomes 3. Existing QIs for elderly patients in ED and, where relevant, non-ED settings 4. Quality management in ED including: structure and feasibility of QIs; barriers to achieving quality of care in EDs; benchmarking in EDs; quality improvement projects in EDs. National Health and Medical Research Council (NHMRC) guidelines for systematic review of scientific literature will be followed Inhibitors,research,lifescience,medical for each core concept . This will include the identification of relevant MeSH/search terms; a search of the peer-reviewed and gray literature; and a hand search of bibliography and reference lists. Using the identified literature, a preliminary list of potential domains for 17-DMAG (Alvespimycin) HCl sourcing QIs will be formulated (EB, LS). The resultant literature summary and the preliminary list of potential QI-domains will then be distributed to an expert panel for review, and to initiate discussion at the expert panel meeting. The first time, the expert panel will meet for two days. The meeting will commence with a presentation of the study, an overview of QI development methodology and a discussion of potential data collection tools. For the remaining time, the Chair (MMK) will lead the panel through a formal process of review for each domain.